San Raffaele Scientific Institute, Milan, Italy.
J Immunol Methods. 2012 Jan 31;375(1-2):46-56. doi: 10.1016/j.jim.2011.09.005. Epub 2011 Sep 22.
Delineation of the immune correlates of protection in natural infection or after vaccination is a mandatory step for vaccine development. Although the most recent techniques allow a sensitive and specific detection of the cellular immune response, a consensus on the best strategy to assess their magnitude and breadth is yet to be reached. Within the AIDS Vaccine Integrated Project (AVIP http://www.avip-eu.org) we developed an antigen scanning strategy combining the empirical-based approach of overlapping peptides with a vast array of database information. This new system, termed Variable Overlapping Peptide Scanning Design (VOPSD), was used for preparing two peptide sets encompassing the candidate HIV-1 vaccine antigens Tat and Nef. Validation of the VOPSD strategy was obtained by direct comparison with 15mer or 20mer peptide sets in a trial involving six laboratories of the AVIP consortium. Cross-reactive background responses were measured in 80 HIV seronegative donors (HIV-), while sensitivity and magnitude of Tat and Nef-specific T-cell responses were assessed on 90 HIV+ individuals. In HIV-, VOPSD peptides generated background responses comparable with those of the standard sets. In HIV-1+ individuals the VOPSD pools showed a higher sensitivity in detecting individual responses (Tat VOPSD vs. Tat 15mers or 20mers: p≤0.01) as well as in generating stronger responses (Nef VOPSD vs. Nef 20mers: p<0.001) than standard sets, enhancing both CD4 and CD8 T-cell responses. Moreover, this peptide design allowed a marked reduction of the peptides number, representing a powerful tool for investigating novel HIV-1 candidate vaccine antigens in cohorts of HIV-seronegative and seropositive individuals.
在自然感染或接种疫苗后,明确免疫保护相关因素是疫苗开发的必要步骤。尽管最近的技术可以敏感和特异地检测细胞免疫反应,但仍未达成评估其幅度和广度的最佳策略共识。在艾滋病疫苗综合项目(AVIP http://www.avip-eu.org)中,我们开发了一种抗原扫描策略,该策略结合了重叠肽的经验方法和大量数据库信息。这种新系统称为可变重叠肽扫描设计(VOPSD),用于制备涵盖候选 HIV-1 疫苗抗原 Tat 和 Nef 的两种肽集。通过与 AVIP 联盟的六个实验室的 15 肽或 20 肽集进行直接比较,验证了 VOPSD 策略的有效性。在涉及 80 名 HIV 阴性供体(HIV-)的试验中测量了交叉反应性背景反应,而在 90 名 HIV+个体中评估了 Tat 和 Nef 特异性 T 细胞反应的敏感性和幅度。在 HIV-中,VOPSD 肽产生的背景反应与标准集相当。在 HIV-1+个体中,VOPSD 池在检测个体反应(Tat VOPSD 与 Tat 15 肽或 20 肽:p≤0.01)以及产生更强的反应(Nef VOPSD 与 Nef 20 肽:p<0.001)方面具有更高的敏感性,增强了 CD4 和 CD8 T 细胞反应。此外,这种肽设计允许显著减少肽数量,这是在 HIV 阴性和阳性个体队列中研究新型 HIV-1 候选疫苗抗原的有力工具。